Mylan isn’t a traditional drug developer, but its 500+% price increase since 2007 for its EpiPen (epinephrine) Auto-Injector for life-threatening allergic reactions has focused more unflattering attention on “big pharma”—just a year after “pharma bro” Martin Shkreli’s infamous 5,000% price hike for Daraprim. On September 21, Mylan CEO Heather Bresch is expected to testify at a hearing of the House Oversight and Government Reform Committee—though if past hearings are any indication, Congress is more likely to generate heat than shed light on the industry.
